Ultragenyx Pharmaceutical
RARE
161 hedge funds and large institutions have $1.81B invested in Ultragenyx Pharmaceutical in 2016 Q2 according to their latest regulatory filings, with 22 funds opening new positions, 60 increasing their positions, 59 reducing their positions, and 21 closing their positions.
5% more first-time investments, than exits
New positions opened: 22 | Existing positions closed: 21
2% more repeat investments, than reductions
Existing positions increased: 60 | Existing positions reduced: 59
0% more funds holding
Funds holding: 161 → 161 (0)
14% less call options, than puts
Call options by funds: $5.47M | Put options by funds: $6.35M
23% less capital invested
Capital invested by funds: $2.35B → $1.81B (-$535M)
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$15.7M |
| 2 |
PAMU
Pictet Asset Management (UK)
London,
United Kingdom
|
+$12.1M |
| 3 |
Lord, Abbett & Co
Jersey City,
New Jersey
|
+$11.7M |
| 4 |
Millennium Management
New York
|
+$11.3M |
| 5 |
Goldman Sachs
New York
|
+$10.6M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VAM
Visium Asset Management
New York
|
-$33.9M |
| 2 |
RIM
RS Investment Management
San Francisco,
California
|
-$25.3M |
| 3 |
Wells Fargo
San Francisco,
California
|
-$24.6M |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$24.6M |
| 5 |
Allianz Asset Management
Munich,
Germany
|
-$6.58M |
RARE Hedge Fund Activity: Q2 2016 in Review
161 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in Ultragenyx Pharmaceutical (RARE) for Q2 2016, worth a combined $1.81B — down 23% from $2.35B a quarter earlier.
Buyers outnumbered sellers: 22 funds opened new RARE positions and 21 closed out — a net gain of 1 holder — while 60 added to existing stakes and 59 trimmed.
The largest buyer was T. Rowe Price Associates, adding an estimated $15.7M. The largest seller was Visium Asset Management, exiting entirely with an estimated $33.9M sold.
- 161 institutional investors held Ultragenyx Pharmaceutical (RARE) as of Q2 2016, unchanged from Q1 2016.
- Funds reported $1.81B of Ultragenyx Pharmaceutical stock for Q2 2016, down 23% quarter-over-quarter.
- 22 funds opened new Ultragenyx Pharmaceutical positions in Q2 2016 and 21 closed out, a net change of +1 holder.
- The largest Ultragenyx Pharmaceutical buyer in Q2 2016 was T. Rowe Price Associates, an estimated $15.7M added.
- The largest Ultragenyx Pharmaceutical seller in Q2 2016 was Visium Asset Management, an estimated $33.9M sold.
Based on aggregated 13F filings for Q2 2016.